Emily A Kendall1, Betina Durovni, Neil A Martinson, Solange Cavalacante, Katlego Masonoke, Valeria Saraceni, Limakatso Lebina, Anne Efron, Silvia Cohn, Sandy Chon, Richard E Chaisson, David W Dowdy, Jonathan E Golub. 1. Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA Center for Strategic Studies, Fundação Oswaldo Cruz Secretaria Municipal de Saúde do Rio de Janeiro, Rio de Janeiro, Brazil Perinatal HIV Research Unit (PHRU), South African Medical Research Council (SAMRC) Soweto Matlosana Collaborating Centre for HIV/AIDS and TB, University of Witwatersrand, Johannesburg, South Africa Evandro Chagas National Institute of Infectious Diseases - Fiocruz, Rio de Janeiro, Brazil Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Abstract
OBJECTIVES: Tuberculosis preventive therapy for people living with HIV is effective, widely recommended, and increasingly prescribed, but completion rates are less than ideal, and adherence is not typically monitored. We sought to quantify adherence to isoniazid preventive therapy using a urine metabolite assay. DESIGN: Two cross-sectional surveys. SETTING: Rio de Janeiro, Brazil, 2008-2009; and Northwest Province, South Africa, 2018-2019. PARTICIPANTS: Two hundred and three Brazilian and 93 South African patients attending HIV clinics with active prescriptions for isoniazid preventive therapy MAIN OUTCOME MEASURES:: Self-reported isoniazid adherence, paired with semiquantitative measurement of urine isoniazid metabolites. RESULTS: By self-report, 90% of patients [95% confidence interval (CI) 86-93%] reported having taken a dose of isoniazid on the day of enrollment or the preceding day, and 91% (95% CI 87-94%) reported missing an average of one dose or fewer per week. By urine testing, only 65% (95% CI 59-70%) of all patients, and 69% (95% CI 63-74%) of those who reported having taken isoniazid on the current or preceding day, had detectable urine metabolites (expected in 95% of patients at 24 h). Longer time since starting preventive therapy was independently associated with a negative urine test for isoniazid metabolites (adjusted prevalence ratio 1.11 per month of isoniazid, 95% CI 1.05-1.18). CONCLUSION: Adherence to isoniazid preventive therapy among patients with HIV in Brazil and South Africa is inadequate, is overestimated by self-report, and declines with time on treatment. Shorter regimens for TB preventive therapy may improve adherence and completion, but adherence support for all patients may be necessary.
OBJECTIVES: Tuberculosis preventive therapy for people living with HIV is effective, widely recommended, and increasingly prescribed, but completion rates are less than ideal, and adherence is not typically monitored. We sought to quantify adherence to isoniazid preventive therapy using a urine metabolite assay. DESIGN: Two cross-sectional surveys. SETTING: Rio de Janeiro, Brazil, 2008-2009; and Northwest Province, South Africa, 2018-2019. PARTICIPANTS: Two hundred and three Brazilian and 93 South African patients attending HIV clinics with active prescriptions for isoniazid preventive therapy MAIN OUTCOME MEASURES:: Self-reported isoniazid adherence, paired with semiquantitative measurement of urine isoniazid metabolites. RESULTS: By self-report, 90% of patients [95% confidence interval (CI) 86-93%] reported having taken a dose of isoniazid on the day of enrollment or the preceding day, and 91% (95% CI 87-94%) reported missing an average of one dose or fewer per week. By urine testing, only 65% (95% CI 59-70%) of all patients, and 69% (95% CI 63-74%) of those who reported having taken isoniazid on the current or preceding day, had detectable urine metabolites (expected in 95% of patients at 24 h). Longer time since starting preventive therapy was independently associated with a negative urine test for isoniazid metabolites (adjusted prevalence ratio 1.11 per month of isoniazid, 95% CI 1.05-1.18). CONCLUSION: Adherence to isoniazid preventive therapy among patients with HIV in Brazil and South Africa is inadequate, is overestimated by self-report, and declines with time on treatment. Shorter regimens for TB preventive therapy may improve adherence and completion, but adherence support for all patients may be necessary.
Authors: Jonathan E Golub; Silvia Cohn; Valeria Saraceni; Solange C Cavalcante; Antonio G Pacheco; Lawrence H Moulton; Betina Durovni; Richard E Chaisson Journal: Clin Infect Dis Date: 2014-11-02 Impact factor: 9.079
Authors: U Egere; A Sillah; T Togun; S Kandeh; F Cole; A Jallow; A Able-Thomas; M Hoelscher; N Heinrich; P C Hill; B Kampmann Journal: Public Health Action Date: 2016-12-21
Authors: Molebogeng X Rangaka; Robert J Wilkinson; Andrew Boulle; Judith R Glynn; Katherine Fielding; Gilles van Cutsem; Katalin A Wilkinson; Rene Goliath; Shaheed Mathee; Eric Goemaere; Gary Maartens Journal: Lancet Date: 2014-05-13 Impact factor: 79.321
Authors: Sarah J Iribarren; Hannah Milligan; Cristina Chirico; Kyle Goodwin; Rebecca Schnall; Hugo Telles; Alejandra Iannizzotto; Myrian Sanjurjo; Barry R Lutz; Kenneth Pike; Fernando Rubinstein; Marcus Rhodehamel; Daniel Leon; Jesse Keyes; George Demiris Journal: Lancet Reg Health Am Date: 2022-06-10
Authors: Sylvia M LaCourse; Daniel Leon; Nuttada Panpradist; Barbra A Richardson; Elizabeth Maleche-Obimbo; Jerphason Mecha; Daniel Matemo; Jaclyn N Escudero; John Kinuthia; Barry Lutz; Grace John-Stewart Journal: Pediatr Infect Dis J Date: 2021-01 Impact factor: 2.129